Beyfortus Side Effects
Generic name: nirsevimab
Medically reviewed by Drugs.com. Last updated on Oct 14, 2023.
Note: This document contains side effect information about nirsevimab. Some dosage forms listed on this page may not apply to the brand name Beyfortus.
Applies to nirsevimab: intramuscular solution.
Serious side effects of Beyfortus
Along with its needed effects, nirsevimab (the active ingredient contained in Beyfortus) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking nirsevimab:
Incidence not known
- Chest tightness
- cough
- difficulty swallowing
- dizziness
- fast heartbeat
- hives, itching, skin rash
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- unusual tiredness or weakness
Other side effects of Beyfortus
Some side effects of nirsevimab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Rare
- Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
For Healthcare Professionals
Applies to nirsevimab: intramuscular solution.
General
Adverse reactions were reported in 1.2% of patients and most were mild to moderate in intensity.[Ref]
Dermatologic
Uncommon (0.1% to 1%): Rash (including rash macular, rash maculopapular, and rash popular)[Ref]
Local
Uncommon (0.1% to 1%): Injection site reaction (including injection site pain, injection site induration, injection site edema, and injection site swelling)[Ref]
Frequently asked questions
More about Beyfortus (nirsevimab)
- Check interactions
- Compare alternatives
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: other immunostimulants
- En español
Patient resources
Professional resources
Related treatment guides
References
1. (2023) "Product Information. Beyfortus (cvx 307) (nirsevimab (cvx 307))." sanofi pasteur
2. (2023) "Product Information. Beyfortus (cvx 306) (nirsevimab (cvx 306))." sanofi pasteur
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.